Table 2 Comparison between tocilizumab and abatacept initiators in terms of mean change in CDAI, mean change in mHAQ, and achievement of low disease activity from baseline to 6 months

Continuous

Mean ± SD

Mean ± SD

β (95% CI)

p value

 Change in CDAI

n = 259, –9.9 ± 14.1

n = 257, –11.3 ± 14.7

–1.27 (–3.65, 1.11)

0.30

 Change in mHAQ

n = 263, –0.11 ± 0.49

n = 264, –0.12 ± 0.42

–0.01 (–0.09, 0.06)

0.83

Binary

Response rate

Response rate

OR (95% CI)

p value

 Achievement of LDA

n = 259

n = 257

(CDAI at time of switch was imputed for switchers)

86 (33.2%)

85 (33.1%)

0.99 (0.69, 1.43)

0.97